Original price was: £35.99.£29.99Current price is: £29.99.
-17%for orders over £200
AOD9604 peptide is a modified version of the hGH fragment 176-191 peptide which is a 191 amino acid peptide. Originally developed in the 1990s, as a fat burning (lipolytic) compound, AOD9604 stimulates the breakdown or destruction of fat cells (lipolysis) and inhibits the metabolic formation of fat (lipogenesis) in animal studies.
Other recent findings have shown, that in addition to its fat loss properties, AOD 9604 processes many other regenerative properties associated with growth hormone. AOD9604 peptide has shown benefits in studies of heart disease, bone /cartilage repair, and metabolic syndrome.
AOD9604 peptide has been shown to:
Regulate the body’s metabolism,
Stimulate the body’s natural fat-burning process
Triggers release of fat from obese fat cells
Decreases the growth of new fat cells
No effects on appetite or blood sugar
Help bone and cartilage repair
This product is prepared for RESEARCH USE ONLY and may not be used for other purposes
AOD9604 is a modified form of the Amino Acid 176-191 of the GH polypeptide. AOD9604 (Advanced Obesity Drug) was developed by Professor Frank Ng at Monash University in Australia in the 1990s, with the intent of finding an anti-obesity drug that had the fat-burning effects of human growth hormone.
This peptide does not appear to affect IGF-I or insulin levels therefore it is not a risk factor for promoting glucose intolerance or diabetes. As AOD9604 is similar enough in structure to natural HGH it appears to avoid the body’s immune system response and there is no evidence the body forms antibodies against it. A phase 2b clinical trial was completed in Australia on 300 obese individuals. The results of once daily administration of the peptide for 12 weeks showed that it tripled weight loss when compared to placebo and the rate of weight loss remained steady. Researchers concluded that resistance to the peptide is unlikely to arise from long-term treatment and greater weight loss may be shown over time.
Research in rats that had AOD9604 injected directly into the joints showed that it works to reduce disability, improve pain and improve quality of life. AOD9604 has also been shown to have shown effects on heart disease through fat reduction and weight loss directly reducing the risk of heart disease.
Structure
Ng, F. M., Sun, J., Sharma, L., Libinaka, R., Jiang, W. J., & Gianello, R. (1999). Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Hormone research, 53(6), 274-278.
Pöykkö, S. M., Kellokoski, E., Hörkkö, S., Kauma, H., Kesäniemi, Y. A., & Ukkola, O. (2003). Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. Diabetes, 52(10), 2546-2553.
Atkinson, T. J. (2008). Central and peripheral neuroendocrine peptides and signalling in appetite regulation: considerations for obesity pharmacotherapy. Obesity reviews, 9(2), 108-120.
Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone F M Ng 1, J Sun, L Sharma, R Libinaka, W J Jiang, R Gianello
Affiliations expand PMID: 11146367 DOI: 10.1159/000053183
All articles and product information on this website are for educational purposes only. These products are not medicines or drugs and have not been approved to treat or cure any medical condition.
© 2022 All Rights Reserved
Products shown on this website are prepared for RESEARCH USE ONLY and may not be used for other purposes.
